With over 2,400 people dead in West Africa from Ebola infections, and thousands more infected with the virus, the outbreak could last for years and spread to other countries if not brought under control quickly, said a U.S. Centers for Disease Control official. The need for additional therapies and eventually a vaccine is critical. 

Poll Question:
Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?



Previous articleGetting Better Western Results
Next articleMerger-Bound Auxilium Mulls Endo’s $2.2B Proposal